Galux, a South Korean AI‑driven protein design biotech, signed a research agreement with Boehringer Ingelheim to validate AI approaches for designing purpose‑specific therapeutic proteins. The initial phase will test whether generative and predictive models can produce proteins that meet defined translational criteria where traditional methods struggle. Galux brings recent de‑novo antibody design milestones—novel antibodies with high affinity and stability—into the collaboration; Boehringer provides drug discovery expertise and translational pathways. The effort aims to move AI beyond structure prediction toward purposeful molecular design for therapeutic use. Both companies framed the deal as a feasibility study that could scale into broader R&D initiatives if early cases demonstrate AI‑driven designs meet manufacturability, specificity and functional benchmarks.